Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States.It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates.
